Agios Pharmaceuticals (AGIO) just highlighted a fresh wave of clinical and preclinical data for its mitapivat candidate, aiming to showcase these results at the upcoming American Society of Hematology conference in December. Investors are watching closely as the data spotlight sustained transfusion independence in thalassemia patients and promising signs in animal models for heart health.

Following these headline results, Agios Pharmaceuticals' recent data releases have caught investors’ attention, fueling a notable year-to-date share price return of 27.2%. While momentum has picked up over the past three months, the one-year total shareholder return still sits at -21.5%. This reflects how longer-term holders have faced setbacks even as excitement builds in the short run around the mitapivat program and improving fundamentals.

Curious which other biopharma names could deliver a breakthrough story? Now’s a perfect time to discover opportunities with our See the full list for free.

Given the recent uptick in share price and pipeline progress, investors may wonder whether Agios is undervalued with upside still remaining, or if the market has already factored in this momentum, signaling a limited window for bargain hunters.

Most Popular Narrative: 14.7% Undervalued

Agios Pharmaceuticals’ most widely followed narrative suggests the company’s fair value sits at $47.50, around 14.7% above its last close of $40.51. This perspective sets the stage for the underlying catalysts and bold assumptions driving analyst conviction on the stock’s upside case.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market. This is driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Want to know what’s powering this bullish target? A rapid-fire combination of projected revenue leaps and a future profit multiple that turns heads is at the core of the narrative. Which bold financial levers make the discount rate and future scenario so ambitious? Unpack the high-stakes growth logic behind the analyst forecast. There’s more behind the numbers than most expect.

Result: Fair Value of $47.50 (UNDERVALUED)

However, setbacks in PYRUKYND's approval process or safety concerns could disrupt Agios’ growth story and challenge the bullish valuation thesis.

Build Your Own Agios Pharmaceuticals Narrative

If you think there’s more to the story or want to dive into the numbers yourself, you can craft your own view in just a few minutes, all your way with Do it your way.

A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t wait for the next breakout to pass you by. Act now and spot your next big opportunity with these unique stock ideas, available to you today.

• Accelerate your search for high-potential growth stories by checking out these 26 AI penny stocks, which are reshaping industries through artificial intelligence innovation.
• Benefit from steady income streams and take a closer look at these 20 dividend stocks with yields > 3%, which are offering yields above 3% for income-focused investors.
• Capitalize on untapped value by investigating these 838 undervalued stocks based on cash flows, where market pricing may not reflect true future potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.